Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Exopolysaccharides (EPSs) from B. breve 091109 + Galactooligosaccharides (GOS) + Konjac glucomannan (KGM) & Glucose Intolerance / Prediabetes

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical trials

NCT05400525 - Exopolysaccharides (EPSs) from B. breve 091109 + Galactooligosaccharides (GOS) + Konjac glucomannan (KGM) & Glucose Intolerance / Prediabetes

This randomized clinical treatment trial revealed that altering the human gut microbiome by means of dietary interventions might offer a promising therapeutic strategy for managing prediabetes and potentially preventing or delaying the onset of diabetes (1).

References

(1) Beteri et al. 2024 Nutrients 16(14): 2205

see also:
Glucose Intolerance / Prediabetes & Drugs/Treatments
[Prebiotics & Glucose Intolerance / Prediabetes](brain://YP8uBKemLE-8Wzefzgk2WQ/…

References (Sources)

Impact of combined prebiotic galacto-oligosaccharides and bifidobacterium breve-derived postbiotic on gut microbiota and HbA1c in prediabetic adults: a double-blind, randomized, placebo-controlled study
Beteri et al. 2024 Nutrients 16(14): 2205

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!